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Excimer laser coronary angioplasty (ELCA) is the 
newest modality in the armamentarium of the inter- 
ventional cardiologist for the percutaneous recanal- 
ization of coronary artery stenoses. Since the intro- 
duction of coronary balloon angioplasty (PTCA) in 
1977 by the late Andreas Gruntzig,’ balloon catheter 
systems have improved considerably. In the follow- 
ing years, the indication for PTCA gradually ex- 
panded to include patients with multivessel disease 
and complex coronary obstructions. More recently, a 
variety of new nonballoon devices have been intro- 
duced2 to specifically address coronary lesions with a 
morphology not ideal for conventional PTCA. Of 
these new techniques, directional and rotational 
atherectomy and ELCA bring about debulking of 
coronary atherosclerotic tissue mass. Removal of 
atherosclerotic plaque by resection or ablation is 
thought to potentially increase immediate success 
rates, reduce acute complication rates, and improve 
long-term results in the percutaneous treatment of 
and Technolas (Grafelfing, Germany)s have been re- 
ported. Recently, multicenter results that involved 
more than 2100 patients and 2500 lesions treated 
with ELCA with these respective laser systems were 
presented.‘e-I” The procedural success rate in the 
ELCA registry of AIS, which includes 1570 patients, 
was as high as 89 VC ,l” and clinical success in a regis- 
try of Spectranetics laser procedures (487 patients) 
was achieved in 85% .ll The six-month restenosis rate 
after ELCA, however, does not appear to be lower 
than after balloon PTCA alone.“, 8+ g, is 
The purpose of this article is to present the first 
results of ELCA in the Netherlands with regard to 
immediate efficacy and safety of use of the laser sys- 
tem that was developed by AIS. These results are 
then discussed in view of the initial experience of 
other centers and recent data from multicenter reg- 
istries of ELCA procedures. Finally, the rationale 
and design of a randomized study of ELCA versus 
conventional PTCA is described. 
complex coronary lesions. 
Since the first patient with coronary artery disease METHODOLOGY 
was treated with ELCA in August 1988,3 experience 
with this technique has grown rapidly. Early and late 
results of ELCA with a pulsed XeCl excimer laser at 
308 nm in combination with multiple-fiber over-the- 
wire laser catheters of various diameters developed 
by Advanced Interventional Systems (AIS) (Irvine, 
Calif.),‘- Spectranetics (Colorado Springs, Cola.),‘, s 
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Since the introduction of ELCA in the Netherlands 
in February 1990 until September 1991, 71 patients 
with 72 lesions were selected to undergo ELCA with 
the laser system that was developed by AIS. The ini- 
tial results obtained at the Academic Medical Center 
in Amsterdam until December 1990 (Fig. 1, period I) 
has recently been published.14 The Thoraxcenter in 
Rotterdam started performing ELCA with the AIS 
laser in December 1990. The joint experience in both 
centers from December 1990 until September 1991 
(Fig. 1, period II) is reported here. 
Patients. In period II 1009 patient,s underwent 
PTCA in the two centers; of these, 53 patients with 
53 lesions were selected for ELCA on the basis of 
previous experience with ELCA by our group and 
other groups. All patients had symptomatic coronary 
artery disease and/or objective evidence of myocar- 
dial ischemia and had been accepted for a percuta- 
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Fig. 1. Overview of past experience with ELCA in the Netherlands with the use of the laser system de- 
veloped by Advanced Interventional Systems, Inc. Results of ELCA from December 1990 to September 1991 
(period II; 53 lesions in 53 patients) are described. 
neous transluminal coronary intervention. The male 
to female ratio was 40:13, and the age (mean -t SD) 
was 59 + 10 years with a range of 40 to 77 years. Most 
patients (45 of 53; 85 % ) were in New York Heart As- 
sociation (NYHA) functional class III or IV for 
angina pectoris (Fig. 2, A). Twenty-five lesions were 
located in the distribution of the left anterior de- 
scending coronary artery, 17 in the right coronary ar- 
tery, and 9 lesions were located in the left circumflex 
coronary artery. Two patients underwent ELCA for 
a significant stenosis in the main stem of the left cor- 
onary artery, which was protected by an aortacoro- 
nary bypass graft. Forty-five of the 53 lesions (85 %) 
were classified as type B or C according to the joint 
American College of Cardiology/American Heart As- 
sociation (ACC/AHA) Task Force criteria15 (Fig. 2, 
B). With growing experience, more patients with type 
B and C lesions were included in the series. 
Laser system. The laser system used consisted of an 
XeCl excimer laser (Advanced Interventional Sys- 
tems, Inc., Irvine, Calif.) emitting light pulses at 308 
nm in the ultraviolet portion of the electromagnetic 
spectrum with a pulse duration of about 200 ns and 
a repetition rate of 20 Hz. Multifiber over-the-wire 
laser catheters of 1.3, 1.6, and 2.0 mm diameter were 
coupled to the laser, and fluence at the catheter tip 
was set at levels of 45 to 60 mJ/mm2. 
Procedure. All patients were pretreated with a cal- 
cium-channel entry blocker, and aspirin was either 
continued orally or given intravenously at the begin- 
ning of the procedure. After insertion of arterial and 
venous introducer sheaths into the femoral vessels, a 
heparin bolus of 10.000 IU was administered. Addi- 
tional doses of 5.000 IU heparin were given in order 
to achieve an activated clotting time of at least 400 
seconds for the duration of the procedure. Standard 
coronary angioplasty guide catheters (Schneider, 
Inc., Minneapolis, Minn.) of 9F for the 1.3 mm laser 
catheter and 9F superflow for 1.6 and 2.0 mm laser 
catheters were used. Intracoronary nitroglycerin was 
given to reduce vasomotor tone, and contrast arteri- 
ography was performed in at least two projections 
(orthogonal if possible). 
After passage of a 0.018 inch guide wire across the 
stenosis into the distal part of the vessel under fluo- 
roscopic control, fluence at the laser catheter tip was 
calibrated, and the catheter was advanced over the 
guide wire until its tip was just proximal to the lesion. 
The laser was then activated for 2 to 3 seconds, and 
the fiberoptic catheter was slowly advanced over the 
guide wire without forceful pushing. During laser ac- 
tivation, the guide wire was kept under slight tension 
or slowly retracted. Each 2- to 3-second pulse train 
was followed by a pause of 3 to 5 seconds with repo- 
sitioning of the guide wire into the most distal part 
of the vessel. In all but two cases in which the lesion 
was passed twice, only one pass with a laser catheter 
was performed through the lesion, after which a con- 
trol angiogram was made. If the residual stenosis was 
more than 50%) the lesion was passed with a larger 
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Fig. 2. A, Distribution of severity of angina pectoris according to New York Heart Association functional 
classification and; 6, distribution of coronary lesion complexity according to ACCIAHA Task Force crite- 
ria in 53 patients selected to undergo ELCA. 
diameter laser catheter or adjunctive balloon PTCA 
was performed. When the result was considered sat- 
isfactory (i.e., a diameter stenosis of less than 50”( 
on visual inspection), final control angiography was 
performed in multiple projections after intracoro- 
nary administration of nitroglycerin. 
After ELCA, the patients were monitored for 24 
hours and 1%lead ECGs and cardiac enzyme levels 
were obtained twice a day. Six hours after the proce- 
dure, the sheaths were pulled out. After recanaliza- 
tion of a total or subtotal occlusion, however, the pa- 
tient was maintained on a heparin drip until the next 
morning; then heparin was discontinued and the 
sheaths were removed. The specific post-ELCA drug 
regimen consisted of aspirin for 6 months after the 
procedure. 
Definition of success. Laser success was prospec- 
tively defined as a more than 20% reduction in 
diameter stenosis after ELCA alone as assessed by 
visual analysis of the angiogram. Procedural success 
was defined as a less than 50% residual stenosis on 
visual assessment at the end of the procedure, whether 
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achieved by ELCA alone or after adjunctive balloon 
PTCA. Clinical success was defined as procedural 
success without death, nonfatal myocardial infarc- 
tion, coronary artery bypass grafting (CABG), or re- 
peat PTCA during the same hospitalization period as 
the laser procedure. Myocardial infarction was 
thought to be present when serum creatine kinase 
rose over twice the normal upper limit of our labora- 
tory, along with a typical elevation of the MB 
fraction. 
Quantitative coronary angiography. Quantitative cor- 
onary angiography was performed on 31 patients who 
were actually undergoing ELCA in the Thoraxcenter. 
Coronary angiograms before ELCA, after ELCA, 
and, if applicable, after adjunctive balloon PTCA 
(n = 25) were analyzed quantitatively with the com- 
puter-assisted Cardiovascular Angiography Analysis 
System (Pie Medical, Maastricht, The Netherlands), 
which has previously been described in detail.16 In 
brief, an optically magnified portion of a selected 35 
mm tine frame encompassing the segment of interest 
is converted into video format by means of a cine- 
video converter. The contours of the vessel segment 
are detected automatically and corrected for pin- 
cushion distortion, which is caused by the image in- 
tensifier. The minimal luminal diameter of the 
stenotic segment is determined in absolute millime- 
ters by using the guide catheter as a scaling device. A 
computer estimation of the original dimension of the 
artery at the site of the obstruction is used to define 
the interpolated reference diameter. The percent di- 
ameter stenosis can then be calculated. Minimal lu- 
minal diameters, reference diameters, and percent 
diameter stenoses were obtained by analysis of the 
artery in at least two matched views, orthogonal if 
possible, and averaged. 
Statistical analysis. Results of quantitative coro- 
nary angiography are presented as mean values k 1 
SD. Comparison between groups (before ELCA, after 
ELCA, and after PTCA) was performed with paired 
and unpaired two-tailed Student’s t tests. A p value 
of <0.05 was considered to indicate a significant dif- 
ference. 
OBSERVATIONS 
Overall results by visual assessment. Of the 53 
patients who were selected to undergo ELCA in both 
centers during period II (Fig. 1)) 50 underwent actual 
treatment with the AIS laser system (Fig. 3, 
intention-to-treat principle). In two patients an in- 
timal dissection occurred during guide wire manipu- 
lation after which ELCA was cancelled; one patient 
underwent subsequent successful balloon PTCA, and 
the other patient was referred for elective CABG. 
The third failure was caused by a technical problem 
with the laser. Immediate laser success was achieved 
in 41 of the 50 patients who underwent ELCA. In two 
patients the laser catheter did not cross the lesion; in 
three other patients an acute occlusion occurred af- 
ter laser ablation, and in the remaining four patients 
diameter stenosis was considered as not being re- 
duced by at least 20% after ELCA alone on visual 
assessment. Thirty-seven of 50 patients (74%) un- 
derwent adjunctive balloon PTCA. After PTCA cor- 
onary occlusion occurred in two more patients and 
was successfully treated by additional balloon dila- 
tations. 
Procedural success was achieved in 48 patients. 
One patient had a “sustained” coronary occlusion 
after ELCA despite multiple balloon dilatations, 
stent implantation, and intracoronary thrombolysis. 
After an autoperfusion balloon catheter was posi- 
tioned and coronary flow was adequately restored, 
the patient was referred for emergency CABG. In 
another patient a distal coronary occlusion developed 
after dissection of the treated segment, and the pa- 
tient had a small myocardial infarction. After com- 
pletion of the procedure (ELCA with or without ad- 
junctive PTCA) and removal of the guide catheter, 
four patients had symptoms and signs of myocardial 
ischemia within 24 hours of the initial procedure, 
which necessitated coronary angiography and repeat 
intervention. In two patients a total occlusion was 
found to result in a myocardial infarction in both, 
despite successful balloon PTCA in one patient. Two 
other patients underwent successful repeat PTCA 
because of early recurrence of the previously treated 
stenosis that caused angina pectoris. Overall, clinical 
success was achieved in 44 patients (83 ‘0 ). In Fig. 4, 
success rates are depicted graphically. 
Complications. Procedural complications, that is 
those that occurred before removal of the guide 
catheter, are summarized in Table I. Intimal dissec- 
tion was primarily associated with adjunctive PTCA 
after ELCA and was limited to types A and B 
according to the classification of Dorros et all7 A 
transient occlusion after ELCA in four patients could 
be resolved by subsequent balloon PTCA. No coro- 
nary perforations (i.e., extravasation of contrast me- 
dium) were noted. Clinical complications that oc- 
curred during the hospitalization period are listed in 
Table II and are mutually exclusive; that is, only the 
most severe event in the ranking order (death, non- 
fatal myocardial infarction, emergency CABG, and 
repeat PTCA) is counted in an individual patient. 
Quantitative coronary angiography. The immediate 
efficacy of ELCA (n = 31 lesions) with adjunctive 
PTCA (72 = 25 lesions) as assessed by quantitative 
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Fig. 3. Flow chart showing procedural and clinical complications in 53 patients (pts) selected for ELCA. 
For definitions of success, see text. CABG, Coronary artery bypass grafting; MI, myocardial infarction; 
PTCA, percutaneous transluminal coronary balloon angioplasty. 
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Fig. 4. Success rates in 53 patients (intention-to-treat analysis) selected to undergo ELCA on the basis 
of visual assessment of the angiogram with categorical cutoff criteria. For definitions of success, see text. 
Thirty-seven patients (74%) had adjunctive balloon angioplasty (PTCA) after ELCA. 
coronary angiography is shown in Figs. 5 and 6. Pre- 
procedural minimal luminal diameter was 0.77 f 
0.41 mm. ELCA significantly improved minimal lu- 
men diameter to 1.24 t- 0.25 mm (p < O.OOOl), and 
with PTCA, it further increased to 1.67 k 0.29 mm 
(p < 0.0001). Reference diameter did not change sig- 
nificantly. Thus percent diameter stenosis was re- 
duced from 69 % + 16% to50% f 12% (p < 0.0001) 
after ELCA, and further to 37 70 k 7 00 (p < 0.0001) 
after adjunctive PTCA. 
COMMENTS 
Since the introduction of ELCA in the clinical set- 
ting, profound modifications were brought into cath- 
eter construction, treatment protocol, and patient 
selection. The first clinical laser catheter of AIS con- 
tained 12 200 pm tipped optical fibers and came in 
only one diameter of 1.6 mm.4 At present, catheters 
are available in multiple sizes that range from 1.3 to 
2.4 mm and contain hundreds of 50 pm fibers. The 
incorporation of a greater number of optical fibers of 
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Fig. 5. Changes in reference diameter (A), minimal luminal diameter (B), and percent diameter stenosis 
(C)before and after ELCA (n = 31), and after adjunctive balloon angioplasty (PTCA) (n = 25). Six patients 
(lesions) had stand-alone ELCA. Reference diameter did not change significantly. Minimal luminal diam- 
eter increased from 0.77 + 0.41 mm to 1.24 f 0.25 mm after ELCA and to 1.67 + 0.29 mm after adjunctive 
balloon PTCA. Percent diameter stenosis decreased from 69% t- 16% to 50% f 12 S/ after ELCA and to 
37’0 2 7% after PTCA. NS Not significant. 
Table I. Procedural complications associated with ELCA in 
period II (N = 53 patients) 
Complication No. of patients 
Intimal dissection 22 
Thrombus formation 7 
Transient occlusion 4 
“Sustained” occlusion 1 
Embolization 1 
smaller diameter has increased catheter flexibility 
and also reduced the area at the tip of the catheter 
that is not available for laser ablation (the so-called 
“dead space”). The dead space between the individ- 
ual fibers at the tip of the catheters used in this study, 
however, still averaged around 80% of the total tip 
area (T. Goldenberg, personal communication). A 
reduction in dead space should reduce the mechan- 
ical dilating or “dottering” effect of a laser catheter 
Table II. Clinical complications associated with ELCA in 
period II (N = 53 patients) 
Complication No. of patients 
Death 0 (0%) 
Nonfatal MI 3 (6%) 
Emergency CABG 1 (2%3 
Repeat PTCA 2 (4%) 
MI, Myocardial infarction; CABG, coronary artery bypass grafting; PTCA, 
percutaneous transluminal coronary angioplasty. 
and iilcreasc: the efficiency of ablation. Also for this 
reason, Auence levels emitted from the catheter have 
been increased from about 40 mJ/mm2 in initial 
ELCA procedures to maximum fluences of around 60 
mJ/mm2,5,6 which is well above the ablation thresh- 
old of noncalcified plaque and probably above the 
threshold for calcified tissue. Thresholds and effi- 
ciency of ablation of calcified plaque by XeCl excimer 
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Fig. 8. Cumulative frequency of immediate results of ELCA and adjunctive balloon angioplasty (PTCA) 
in 31 and 25 lesions, respectively, as assessed by quantitative coronary angiography. MLD, Minimal lumi- 
nal diameter. 
laser radiation have been experimentally deter- 
mined14 lg and depend on the laser pulse duration, 
the medium in which tissue ablation takes place (air, 
saline solution, blood) and the degree of plaque cal- 
cification. Currently, it is well recognized that opti- 
mal debulking of atherosclerotic tissue mass is a pre- 
requisite for a good procedural result with EL- 
CA 13,20,21 
Subacute closure of the treated vessel occurs more 
often after ELCA than after conventional PTCA and 
may result from insufficient tissue ablation,20, Z1 re- 
versible coronary spasm,“2 and/or thrombosis. Lib- 
eral use of intracoronary nitroglycerin is advocated, 
and a strict antiplatelet and anticoagulation protocol 
has been implemented. In addition to aspirin, ade- 
quate doses of heparin are given to keep the activated 
clotting time above 400 seconds for the duration of 
the procedure. Some centers maintain their patients 
on an overnight heparin drip after ELCA in order to 
further reduce thrombotic complications in the sub- 
acute phase. Moreover, adjunctive balloon PTCA is 
now performed in approximately two thirds of pa- 
tients who undergo ELCAiO to optimize the final re- 
sult of the intervention with a minimum of residual 
stenosis. 
Finally, case selection for ELCA has undergone 
considerable change. After it was recognized that 
ELCA did not appear to have an advantage over 
PTCA in uncomplicated and discrete coronary le- 
sions with respect to immediate and long-term out- 
come, there has been a trend toward treating coro- 
nary lesions that are not ideal for conventional 
PTCA, particularly ostial lesions, tubular and diffuse 
disease, saphenous vein grafts, and chronic total oc- 
clusions. On the basis of this development, one may 
anticipate a downward shift in immediate success 
rates as would be expected for PTCA. Data from the 
AISlO and Spectraneticsll registries, however, show 
that lesion length and complexity do not seem to in- 
fluence results. Also, the frequency of major compli- 
cations (CABG, myocardial infarction, death) did not 
differ significantly between lesions with simple or 
complex angiographic morphology.1”v l’ 
Initial immediate results obtained in the first 50 to 
60 patients who were treated with an XeCl excimer 
laser have been reported previously. Litvack et al.” 
achieved 84 % laser success and 93 % procedural suc- 
cess in the first 55 patients who underwent ELCA 
with the AIS system in a prospective, nonrandom- 
ized, multicenter trial. Sanborn et a1.7 reported a 
75 (‘c laser success rate and a 100’,0 procedural 
success rate in the first 50 patients who were treated 
with the Spectranetics laser. Karsch et a1.g reported 
a 70 5 laser success rate and an 88 % procedural suc- 
cess rate in the first 60 patients who were treated with 
the Technolas system. Laser success was somewhat 
lower in the latter patient series, possibly as a result 
of catheter technology and/or subthreshold fluences 
for laser ablation of atherosclerotic tissue used in this 
protocol. It is remarkable that, despite considerable 
modifications in laser catheter design and procedural 
protocol, immediate results of ELCA have not im- 
proved since the first patients were treated. This im- 
plies that initial success rates claimed by pioneering 
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investigators should at least be viewed with healthy 
skepticism. After 3 years of technical developments 
and increasing operator experience, procedural and 
clinical successes in the large multicenter registries 
which now include over 2000 patients, appear to be 
even somewhat lower than in the beginning, namely 
89 ‘To and 85 % , respectively.lO, l1 This observation 
poses questions about the validity of data bases set 
up by companies that sponsor laser systems.“3 One 
can argue, however, that superior results of highly 
experienced investigators may be negated by centers 
that are starting to perform ELCA and initially pro- 
vide unfavorable data to the registry because of their 
learning curve. An important weakness of the current 
registries is that ELCA procedures are assessed by 
visual, and hence, nonobjective analysis of the angio- 
gram with arbitrary, categorical criteria for success. 
Cook et a1.5 recently reported the experience with 
ELCA in the first 100 patients who were treated at 
the Cedars-Sinai Medical Center in Los Angeles with 
the AIS system between July 1988 and March 1990, 
when new laser catheters of 1.3, 1.6, and 2.0 mm in 
diameter became available. Coronary angiograms 
were analyzed with a modification of the method de- 
scribed by Brown et al.,“” a computer-assisted visual 
analysis in which luminal contours are hand-traced. 
Immediate laser success was thus achieved in 84% 
and procedural success in 94% of patients. The 
ACC/AHA Task Force classification of coronary 
lesion morphologyi was used as a basis to compare 
the results of ELCA with the anticipated initial suc- 
cess rates of conventional PTCA. In type A, B, and 
C lesions immediate laser successes were 83 C, ,88 “;, 
and 85 ‘i, respectively, versus 92%) 81 Cr, and 61% 
for balloon PTCA as reported by Ellis et a1.‘5 In ad- 
dition, results were independent of lesion length, a 
separate ACC/AHA Task Force classification char- 
acteristic. For stenoses and total occlusions shorter 
than 10 mm, of 10 to 20 mm, and longer than 20 mm, 
laser success rates were 88%)) 82 U;, , and 80 5:; , respec- 
tively, which were not significantly different. Com- 
plication rates with ELCA in type B and C lesions 
(2 ?F and 0 CG , respectively) also compared favorably 
with PTCA (6%. and 21%) respectively).25 It can be 
concluded from this study5 that ELCA may be a use- 
ful therapy with potential advantages over standard 
balloon PTCA in lesions with certain type B and C 
characteristics. 
Limitations of the study by Cook et a1.5 are the ab- 
sence of an objective quantitative analysis technique 
for coronary angiograms, the presence of selection 
bias, and lack of randomization. Patients were se- 
lected for ELCA on the basis of previous experience 
with laser and balloon angioplasty. Thus many pa- 
tient and lesion characteristics may have been more 
“ideal” for ELCA as opposed to PTCA. Moreover, 
immediate results of ELCA were compared with data 
from registries of conventional PTCA15*25 with the 
use of morphologic criteria that were originally de- 
veloped for balloon angioplasty. The definition of a 
type C lesion, for example, contains a number of dif- 
ferent morphologic criteria, which range from exces- 
sive vessel tortuosity to chronic total occlusion. TWO 
type C lesions are not the same, and lesion charac- 
teristics are likely to not have been similar in the 
ELCA group and PTCA registry patients. In addi- 
tion, definitions of procedural complications, such as 
intimal dissection, may not have been the same, 
which could lead to spurious findings. Careful de- 
scription and comparison of patient and procedural 
characteristics, as well as definitions, are necessary 
for a meaningful comparison between ELCA and 
PTCA registry results.‘6 Ideally, a prospective, ran- 
domized trial of ELCA versus PTCA in which patient 
and lesion characteristics are balanced should be un- 
dertaken to assess the relative benefits of these tech- 
niques in the treatment of a specific and well-defined 
coronary pathologic condition. In this setting, auto- 
mated quantitative coronary angiography is required 
to objectively determine whether “debulking” of an 
atherosclerotic lesion by ELCA would result in supe- 
rior immediate and late outcomes as compared with 
PTCA alone. 
Our experience (Fig. 1, period II) with ELCA as 
described here relates to a population of 53 patients 
with slightly more severe and complex coronary 
artery disease than the initial patient cohort treated 
by Cook et al.,j as judged by angina pectoris New 
York Heart Association functional class (class III and 
IV, 855; vs 74 I’; ) and ACC/AHA Task Force coro- 
nary lesion classification (types B and C, 85% vs 
72% ). In our group no patients were treated with 
ELCA for saphenous vein graft disease, possibly an 
“ideal” indication for this intervention.5 When we 
used similar catheter equipment and medical proto- 
col, we found in our patient group an immediate la- 
ser success rate of 77 5, a procedural success rate of 
91%) and a clinical success rate of 83 % by visual as- 
sessment of the angiogram. These figures fall 5c; to 
lo’? short compared with the immediate outcomes 
reported by the Cedars-Sinai group’ and in the 
ELCA registry of A1S.l’ Important procedural dif- 
ferences include the application of only one pass with 
a particular diameter laser catheter in our protocol, 
whereas multiple (one to five) passes were made 
through the lesion by Cook et al.” Adjunctive PTCA, 
on the other hand, was performed in 74 “C of our pa- 
tients compared with 47 “PI of Cedars-Sinai patients.” 
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This may explain the relatively frequent occurrence 
of intimal dissection in our experience, which was 
primarily associated with adjunctive balloon dilata- 
tion after ELCA. However, the visual interpretation 
of tine angiograms for the presence of angiographic 
success and/or complications is prone to subjectivity, 
depends on the quality of the image, and may suffer 
from different definitions used. When the criteria for 
visual assessment of ELCA success are applied to in- 
dividual quantitative coronary angiographic mea- 
surements of pre-ELCA, post-ELCA, and post-PTCA 
angiograms, laser, procedural, and clinical success 
rates in the present population are 445, 84%) and 
755, respectively. Thus there is considerable dis- 
crepancy between visual and quantitatively deter- 
mined success rates, particularly after ELCA alone, 
when arbitrary, categorical cutoff criteria are used. 
This underscores the importance of a continuous ap- 
proach for the evaluation of ELCA procedures (i.e., 
automated quantitative coronary angiographic anal- 
ysis). Consequently, new criteria that are based on 
absolute measurements of coronary luminal dimen- 
sions should be designed or developed to assess 
results of ELCA in an objective manner. 
The AMRO study. In September 1991 the Academic 
Medical Center (Amsterdam) and the Thoraxcenter 
(Rotterdam) initiated an ongoing cooperative ran- 
domized study of the efficacy of ELCA versus balloon 
PTCA in the treatment of long (I 10 mm) coronary 
stenoses or occlusions. 
Patient selection. The target population includes 
patients with stable angina pectoris and objective 
signs of myocardial ischemia who are scheduled to 
undergo a percutaneous intervention for a coronary 
stenosis (>50% diameter reduction) or occlusion of 
10 mm or longer as visually assessed on the diagnos- 
tic angiogram. Clinical exclusion criteria are unstable 
angina, evolving or recent (within the past 2 weeks) 
myocardial infarction, and contraindication for emer- 
gency CABG. A life expectancy of less than 1 year and 
factors that make clinical or angiographic follow-up 
unlikely also form exclusion criteria. Angiographic 
exclusion criteria are intended angioplasty of a venous 
coronary bypass graft, unprotected left main coro- 
nary artery disease, extreme tortuosity of the vessel 
segment to be treated, highly eccentric lesions, bi- 
furcation lesions, intended angioplasty of a lesion 
with angiographic evidence of thrombus, and total 
occlusion with a very low chance of crossing by guide 
wire. A total of 300 patients will be enrolled in 2 years. 
Randomization and treatment. After written in- 
formed consent is obtained, patients undergo a base- 
line exercise test including technetium (Tc) 99m 
methoxyisobutyl isonitrile (MIBI) single photon 
emission computed tomography (SPECT) and are 
then randomly assigned to one of two treatment 
groups (PTCA or ELCA). All patients are prelreated 
with a calcium-channel entry blocker and receive the 
intervention within 2 days of randomization. Aspirin 
is given before and for 6 months after the procedure: 
heparin is given at the beginning and during the pro- 
cedure to keep the activated clotting time above 400 
seconds, and intracoronary nitroglycerin is given 
during the procedure at the operator’s discretion. All 
patients are maintained on an overnight heparin drip 
until the morning after the procedure. Until hospital 
discharge, 20 mg of nifedipine is given three times 
daily. PTCA is performed with standard technique 
and modern balloon catheter equipment,. The tech- 
nical details of ELCA are described above and will be 
in accordance with the latest insights and AIS clin- 
ical prot.ocol. 
Follow-up. After discharge, patients are seen after 
1 and 6 months. If sympt,oms recur after successful 
angioplasty, medical therapy is first optimized. Six 
months after randomization or when symptoms dic- 
tate, exercise testing with ggmT~ MIBI SPECT and 
repeat quantitative coronary angiography are per- 
formed. During follow-up exercise testing and myo- 
cardial perfusion studies, all medication for angina 
pectoris will be withdrawn if clinical status permits. 
End points. Primary clinical end points of the 
study are the occurrence of any of the following: car- 
diac death, myocardial infarction, CABG, stent im- 
plantation, or repeat PTCA after the initial proce- 
dure. The primary scintigraphic end point is the ex- 
tent of myocardial perfusion as assessed by HgmTc 
MIBI SPECT at followup. The primary angiographic 
end point is the minimal luminal diameter at. the 
treated coronary site at 6 months relative to baseline 
as determined by quantitative analysis with an auto- 
mated contour detection technique (Cardiovascular 
Angiography Analysis System), as described above. 
Secondary end points include patients’ functional 
class for angina pectoris, other quantitative angio- 
graphic parameters (percent diameter stenosis, ref- 
erence diameter, plaque area) at, 6 months relative to 
baseline and evidence of restenosis in the two treat.- 
ment groups according to the various criteria. Fi- 
nally, a cost-benefit analysis will be performed. 
SUMMARY 
The immediate outcome of ELCA by XeCl excimer 
laser radiation is described in 53 patients who were 
selected to undergo ELCA from December 1990 to 
September 1991 in two centers that are currently 
performing ELCA in the Netherlands. Immediate 
success rates on the basis of visual assessment of the 
angiogram were as follows. Laser success (>20’, re- 
duction of diameter stenosis after ELCA alone) was 
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observed in 77% of patients, procedural success 
(<50 % residual stenosis after ELCA with or without 
adjunctive balloon dilatation [PTCA]) in 91% , and 
clinical success (procedural success without clinical 
complications) in 83 50 of patients. Quantitative cor- 
onary angiography by automated contour detection 
was performed in 31 patients who underwent ELCA 
in the Thoraxcenter. The minimal luminal diameter 
(mean -i- SD) of the treated coronary segments in- 
creased from 0.77 + 0.41 mm to 1.24 f 0.25 mm af- 
ter ELCA and further to 1.67 +- 0.29 mm after 
adjunctive PTCA in 25 patients. The present expe- 
rience is put in perspective of results initially re- 
ported by other centers and compared with data from 
multicenter registries of ELCA. Finally, a short 
description is given of the design of a prospective, 
randomized trial of ELCA versus conventional PTCA 
(AMRO trial). 
We thank Eline Montauban van Swijndregt for expert techni- 
cal assistance and Marjolein Wapenaar for preparation of the 
manuscript. 
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